Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dorzagliatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Bayer AG
Deal Size : $635.8 million
Deal Type : Partnership
Bayer and Hua Medicine Announce Commercialization Agreement
Details : Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in Ch...
Brand Name : HMS5552
Molecule Type : Small molecule
Upfront Cash : $43.3 milllion
August 17, 2020
Lead Product(s) : Dorzagliatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Bayer AG
Deal Size : $635.8 million
Deal Type : Partnership
Lead Product(s) : Dorzagliatin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.
Brand Name : HMS5552
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2020
Lead Product(s) : Dorzagliatin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dorzagliatin,Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2020
Lead Product(s) : Dorzagliatin,Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?